NewsWatch: Moderna and SpaceX highlighted by a fast-growing U.S. fund traded in London

Baillie Gifford U.S. Growth Trust devoted much of its half-yearly report to talking up the prospects of biotech Moderna and rocket launcher SpaceX, two of its investments that helped lift its net asset value surge during the time frame.